Look­ing to ex­pand be­yond di­a­betes, No­vo Nordisk en­lists Evotec in CKD pact worth up to $179M per pro­gram

Most of No­vo Nordisk’s kid­ney work has come from di­a­betes, but eye­ing an R&D ex­pan­sion, the Dan­ish gi­ant is putting mon­ey down on a pact …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.